Irinotecan Pharmacogenetics: Is It Time to Intervene?
- 15 April 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (8) , 1356-1359
- https://doi.org/10.1200/jco.2004.01.950
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of IrinotecanJournal of Clinical Oncology, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002
- Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal CancerNew England Journal of Medicine, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's SyndromeNew England Journal of Medicine, 1995
- A New Type of Defect in the Gene for Bilirubin Uridine 5 '-Diphosphate-Glucuronosyltransferase in a Patient with Crigler-Najjar Syndrome Type IPediatric Research, 1994
- Identification of Defect in the Genes for Bilirubin UDP-Glucuronosyltransferase in a Patient with Crigler-Najjar Syndrome Type IIBiochemical and Biophysical Research Communications, 1993